^
    Back
    Association details:
    Biomarker:RET-PTC1 rearrangement
    Cancer:Thyroid Gland Papillary Carcinoma
    Drug:dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) +
    CI-1040 (MEK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Head Neck
    Title:

    Src Inhibitors Suppress the Growth of Papillary Thyroid Carcinoma

    Excerpt:
    In TPC-1 cells after 4 days of treatment, the cell growth was repressed for 36.2 or 71.4% (p < 0.001) by 0.1 or 1 μM PP2, 29.9 or 61.4% (p < 0.001) by 0.1 or 1 μM SU6656, or 36.7 or 69.2% (p < 0.001) by 0.01 or 0.1 μM dasatinib, respectively, when compared to untreated cells...
    DOI:
    10.1002/hed.23316